VYVANSE? Receives Final DEA Schedule Classification, Clearing Way For Launch Of First Prodrug Stimulant For ADHD Treatment

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Drug Enforcement Administration (DEA)has classified VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), as a Schedule II controlled substance, following the earlier recommendation of the U.S. Food and Drug Administration (FDA). [click link for full article]

Read More: continued here

Filed under: ADHD on May 7th, 2007